RI VC Shop Slater Tech Fund Bets $250K on Sentient Bioscience to Develop Embolization Tools

Scientific co-founders of Sentient, which is developing embolization therapy technology and site-specific drug delivery methods to treat cancer and other medical conditions, include researchers from Brown University and Johns Hopkins University.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.